reason report
multi-year rev/ep acceler stori intact pt
bottom line reiter op rate follow
result add convict org rev/ep growth acceler
thesi sustain hsd top-lin profil along mid-
teen ep growth cc revenue adj less sell
day top consensu led management increas full-year
outlook vs despit increment fx headwind
allow management reiter ep rang delay replass fda
bla submiss minor setback product pure
upsid out-year estim continu believ
plenti levers/driv period drive hsd revenu growth
deliv mid-teen ep growth -- -a better profil mani
peer also see upsid potenti out-year forecast
consid model contempl meaning benefit/
contribut manta fda approv expect
drive acceler momentum neotract sale special
japan driver addt restructur initi
pt goe vs assum slightli higher multipl
vs previous heel recent grp multipl expans
appli ep
mostli fx ep y/i ex-fx still deliv
upsid lower tax beat consensu
importantli org cc sell day adjust revenue growth
y/i estim came forecast
out-performance led neotract intervent urolog
cc vascular access cc surgic cc
geograph standpoint deliv strong growth within america
cc beat consensu asia cc in-lin
emea cc slightli due order time
turn gm miss consensu
consensu ebita mgn miss margin
under-perform primarili due fx ebita would
flat y/i higher exclud fx lower interest expens tax
rate help off-set ep beat think
price-to-earnings lt ep growth
medic suppli devic
ep
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep present note valuat base pf ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
increas cc fx headwind vs
cc prior impli top-lin result
rang -- -primarili reflect upsid growth expect broad-
base intervent urology/urolift expect y/i vs
prior intervent access hsd y/i vascular access
surgic msd y/i guidanc assum immateri contribut
percuv manta limit launch could
serv sourc upsid out-year estim possibl even
regard revenue cadenc neg impact
fx benefit one extra sell day net neutral
distributor dynamics/ord time busi
acceler op-ex spend confid
weight y/i op leverag management re-affirmed adj gm guidanc
rang toward low end impli improv
due mfg product legaci restructur
favor higher margin geographic/product mix
off-set increment tariff fx headwind management lower adj
ebita margin guidanc vs contempl
increment fx headwind higher sell expens
proactiv invest protect enhanc futur growth prospect
 qualiti system ip ebita margin improv driven
gm improv better opex leverag interest
expens expect vs prior adj tax
rate expect low end rang adj ep
guidanc ex-fx reiter
neg impact lrp growth target management indic
expect complet bla submiss ezpla
lyophil fresh frozen plasma product
addit question fda requir analysis/test
carri end disappoint temporari
setback note compani lrp contempl minim
contribut revenue product even get
push number driver make
 manta contempl lrp japan urolift
number growth-driv initi repres
upsid estim manta acquir link enter
limit launch us receiv posit physician
feedback continu test price market ensur
appropri train product becom sticki within tavr center
management estim center us manta growth
accel driver management also continu take aim mid-to-
late urolift japan launch bigger ramp acceler
invest behind dtc secur reimburs ramp
meaning meanwhil urolift roll-out remain track
full convers us physician
model updat adjust qtrli revenue cadenc project
revenue vs cc org cc revenue
vs cc org cc sell day adjust
extra sell day revenue increas vs
reflect org cc sell day adj growth vs prior
also adjust margin/ep cadenc align management updat
guidance/commentari revenue model org cc growth
ep growth acceler
outperform rate pt light recent neotract acquisit
see clearer pathway toward hsd org sale growth rang
vascular solut vsi close feb neotract close deal
organ mix strong record execut come integr
includ under-promis over-deliv initi synergy/sal target
less near-term cost synergi potenti associ neotract top-lin accret
potenti excit us deal believ potenti transform
hsd revenu grower out-year also think could addit sales/
ep momentum out-year factor model consid increas
contribut neotract ou market bulk exist urolog footprint
current sit urolift today minim presenc eventu revenue contribut
increas revenue contribut manta acquir essenti medic acquisit
pma approv potenti futur tuck-in addit restructur
opportun addit program alreadi underway project earn power
ep compound-annual-growth-rate op margin expans potenti
given confid top-lin acceler territori mid-teen
ep growth profil -- -both upper-end peersw think sustain
current premium group assum ep suggest pt
trade ep slight premium
peer group hospit suppli compani compani relev
trade ep given confid top-lin acceler hsd
territori margin expans driven acceler mid-to-high teen ep growth profil --
upper-end peersw think fact widen premium
group appli multipl premium group
ep suggest pt wed note compani med-tech msd-hsd top line
valuat could risk new product launch organiz improv effort
planned/prior integr synergi cost-cut effort prove challeng take longer
expect implement neotract acquisit integr time fashion
reason uptak compani urolift platform materi quickli
project could put pro forma sales/ep forecast risk well tough competit
larger hospit suppli compani could hinder abil make inroad new
product launch hospitalsin effort rein cost preserv profit given numer
global macroeconom challeng uncertainti relat political/healthcar reform tighten
belt grow less will negoti price hospit suppli product could make
harder drive higher product compani typic sold
discount market rate attempt bring market rate newli launch
achiev sustain price increas key driver long-term gross/oper margin
improv instrument order achiev long-term sales/profit goal
discret item neg impact organ cc revenue growth compani base busi
prove transient take longer resolv expect would like damag
management credibl decreas investor confid org revenue growth acceler thesi
key part invest thesi
dollar million except ep
svb leerink llc estim factset compani inform
dollar million except ep
svb leerink llc estim compani inform
restat report statement effect januari includ revenu geographi revenu product comparison prior
dollar million except ep
headwind fx greatest impact
headwind fx greatest impact
headwind fx greatest impact
incl invest urolift japan
incl invest urolift japan
 commerci infrastructur
manta well addt
 commerci infrastructur
manta well addt
closer low-end
closer low end
compani report svb leerink llc estim
dollar million except per share data
good sold
oper incom ex-item amort
pre-tax incom ex-item amort
dilut averag share million
sg adjust sale
sg adjust ex-amort sale
 total sale
oper expens adjust sale
oper expens adjust ex-amort sale
day adj sale organ growth rate ex- acq
compani report svb leerink llc estim
 restat segment revenu
dollar million except per share data
sale mix
compani report svb leerink llc estim
restat report statement effect januari includ revenu geographi revenu product comparison prior estim
